Mesenchymal Stem Cells Reconditioned in Their Own Serum Exhibit Augmented Therapeutic Properties in the Setting of Acute Respiratory Distress Syndrome

Abstract Mesenchymal stem cells (MSCs) are a promising form of therapy for acute respiratory distress syndrome (ARDS). The objective of this study was twofold: (a) to characterize cytokine expression in serum from ARDS subjects receiving MSCs and (b) to determine MSC function following “precondition...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Amy L. Xu, Luis A. Rodriguez II, Kerfoot P. Walker III, Arezoo Mohammadipoor, Robin M. Kamucheka, Leopoldo C. Cancio, Andriy I. Batchinsky, Ben Antebi
Formato:	article
Lenguaje:	EN
Publicado:	Wiley 2019
Materias:	Mesenchymal stem cells Acute respiratory distress syndrome Preconditioning Inflammatory mediators Inhalation injury Medicine (General) R5-920 Cytology QH573-671
Acceso en línea:	https://doaj.org/article/b344c35130f34df4ad1208665fff0114
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b344c35130f34df4ad1208665fff0114
record_format	dspace
spelling	oai:doaj.org-article:b344c35130f34df4ad1208665fff01142021-11-30T19:15:37ZMesenchymal Stem Cells Reconditioned in Their Own Serum Exhibit Augmented Therapeutic Properties in the Setting of Acute Respiratory Distress Syndrome2157-65802157-656410.1002/sctm.18-0236https://doaj.org/article/b344c35130f34df4ad1208665fff01142019-10-01T00:00:00Zhttps://doi.org/10.1002/sctm.18-0236https://doaj.org/toc/2157-6564https://doaj.org/toc/2157-6580Abstract Mesenchymal stem cells (MSCs) are a promising form of therapy for acute respiratory distress syndrome (ARDS). The objective of this study was twofold: (a) to characterize cytokine expression in serum from ARDS subjects receiving MSCs and (b) to determine MSC function following “preconditioning” with ARDS serum. In phase I, serum from three cohorts of animals (uninjured [no ARDS, n = 4], injured untreated [n = 5], and injured treated with approximately 6 million per kilogram MSCs [n = 7]) was analyzed for expression of inflammatory mediators. In phase II, the functional properties of bone marrow porcine MSCs were assessed following “preconditioning” with serum from the three cohorts. In phase III, the findings from the previous phases were validated using human bone marrow MSCs (hBM‐MSCs) and lipopolysaccharide (LPS). Serum from injured treated animals had significantly lower levels of interferon‐γ and significantly higher levels of interleukin (IL)‐1 receptor antagonist (IL‐1RA) and IL‐6. Similarly, upon exposure to the injured treated serum ex vivo, the MSCs secreted higher levels of IL‐1RA and IL‐10, dampened the secretion of proinflammatory cytokines, exhibited upregulation of toll‐like receptor 4 (TLR‐4) and vascular endothelial growth factor (VEGF) genes, and triggered a strong immunomodulatory response via prostaglandin E2 (PGE2). hBM‐MSCs demonstrated a similar augmented therapeutic function following reconditioning in a LPS milieu. Administration of MSCs modulated the inflammatory milieu following ARDS. Exposure to ARDS serum ex vivo paralleled the trends seen in vivo, which appear to be mediated, in part, through TLR‐4 and VEGF and PGE2. Reconditioning MSCs in their own serum potentiates their immunotherapeutic function, a technique that can be used in clinical applications. Stem Cells Translational Medicine 2019;8:1092–1106Amy L. XuLuis A. Rodriguez IIKerfoot P. Walker IIIArezoo MohammadipoorRobin M. KamuchekaLeopoldo C. CancioAndriy I. BatchinskyBen AntebiWileyarticleMesenchymal stem cellsAcute respiratory distress syndromePreconditioningInflammatory mediatorsInhalation injuryMedicine (General)R5-920CytologyQH573-671ENStem Cells Translational Medicine, Vol 8, Iss 10, Pp 1092-1106 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	Mesenchymal stem cells Acute respiratory distress syndrome Preconditioning Inflammatory mediators Inhalation injury Medicine (General) R5-920 Cytology QH573-671
spellingShingle	Mesenchymal stem cells Acute respiratory distress syndrome Preconditioning Inflammatory mediators Inhalation injury Medicine (General) R5-920 Cytology QH573-671 Amy L. Xu Luis A. Rodriguez II Kerfoot P. Walker III Arezoo Mohammadipoor Robin M. Kamucheka Leopoldo C. Cancio Andriy I. Batchinsky Ben Antebi Mesenchymal Stem Cells Reconditioned in Their Own Serum Exhibit Augmented Therapeutic Properties in the Setting of Acute Respiratory Distress Syndrome
description	Abstract Mesenchymal stem cells (MSCs) are a promising form of therapy for acute respiratory distress syndrome (ARDS). The objective of this study was twofold: (a) to characterize cytokine expression in serum from ARDS subjects receiving MSCs and (b) to determine MSC function following “preconditioning” with ARDS serum. In phase I, serum from three cohorts of animals (uninjured [no ARDS, n = 4], injured untreated [n = 5], and injured treated with approximately 6 million per kilogram MSCs [n = 7]) was analyzed for expression of inflammatory mediators. In phase II, the functional properties of bone marrow porcine MSCs were assessed following “preconditioning” with serum from the three cohorts. In phase III, the findings from the previous phases were validated using human bone marrow MSCs (hBM‐MSCs) and lipopolysaccharide (LPS). Serum from injured treated animals had significantly lower levels of interferon‐γ and significantly higher levels of interleukin (IL)‐1 receptor antagonist (IL‐1RA) and IL‐6. Similarly, upon exposure to the injured treated serum ex vivo, the MSCs secreted higher levels of IL‐1RA and IL‐10, dampened the secretion of proinflammatory cytokines, exhibited upregulation of toll‐like receptor 4 (TLR‐4) and vascular endothelial growth factor (VEGF) genes, and triggered a strong immunomodulatory response via prostaglandin E2 (PGE2). hBM‐MSCs demonstrated a similar augmented therapeutic function following reconditioning in a LPS milieu. Administration of MSCs modulated the inflammatory milieu following ARDS. Exposure to ARDS serum ex vivo paralleled the trends seen in vivo, which appear to be mediated, in part, through TLR‐4 and VEGF and PGE2. Reconditioning MSCs in their own serum potentiates their immunotherapeutic function, a technique that can be used in clinical applications. Stem Cells Translational Medicine 2019;8:1092–1106
format	article
author	Amy L. Xu Luis A. Rodriguez II Kerfoot P. Walker III Arezoo Mohammadipoor Robin M. Kamucheka Leopoldo C. Cancio Andriy I. Batchinsky Ben Antebi
author_facet	Amy L. Xu Luis A. Rodriguez II Kerfoot P. Walker III Arezoo Mohammadipoor Robin M. Kamucheka Leopoldo C. Cancio Andriy I. Batchinsky Ben Antebi
author_sort	Amy L. Xu
title	Mesenchymal Stem Cells Reconditioned in Their Own Serum Exhibit Augmented Therapeutic Properties in the Setting of Acute Respiratory Distress Syndrome
title_short	Mesenchymal Stem Cells Reconditioned in Their Own Serum Exhibit Augmented Therapeutic Properties in the Setting of Acute Respiratory Distress Syndrome
title_full	Mesenchymal Stem Cells Reconditioned in Their Own Serum Exhibit Augmented Therapeutic Properties in the Setting of Acute Respiratory Distress Syndrome
title_fullStr	Mesenchymal Stem Cells Reconditioned in Their Own Serum Exhibit Augmented Therapeutic Properties in the Setting of Acute Respiratory Distress Syndrome
title_full_unstemmed	Mesenchymal Stem Cells Reconditioned in Their Own Serum Exhibit Augmented Therapeutic Properties in the Setting of Acute Respiratory Distress Syndrome
title_sort	mesenchymal stem cells reconditioned in their own serum exhibit augmented therapeutic properties in the setting of acute respiratory distress syndrome
publisher	Wiley
publishDate	2019
url	https://doaj.org/article/b344c35130f34df4ad1208665fff0114
work_keys_str_mv	AT amylxu mesenchymalstemcellsreconditionedintheirownserumexhibitaugmentedtherapeuticpropertiesinthesettingofacuterespiratorydistresssyndrome AT luisarodriguezii mesenchymalstemcellsreconditionedintheirownserumexhibitaugmentedtherapeuticpropertiesinthesettingofacuterespiratorydistresssyndrome AT kerfootpwalkeriii mesenchymalstemcellsreconditionedintheirownserumexhibitaugmentedtherapeuticpropertiesinthesettingofacuterespiratorydistresssyndrome AT arezoomohammadipoor mesenchymalstemcellsreconditionedintheirownserumexhibitaugmentedtherapeuticpropertiesinthesettingofacuterespiratorydistresssyndrome AT robinmkamucheka mesenchymalstemcellsreconditionedintheirownserumexhibitaugmentedtherapeuticpropertiesinthesettingofacuterespiratorydistresssyndrome AT leopoldoccancio mesenchymalstemcellsreconditionedintheirownserumexhibitaugmentedtherapeuticpropertiesinthesettingofacuterespiratorydistresssyndrome AT andriyibatchinsky mesenchymalstemcellsreconditionedintheirownserumexhibitaugmentedtherapeuticpropertiesinthesettingofacuterespiratorydistresssyndrome AT benantebi mesenchymalstemcellsreconditionedintheirownserumexhibitaugmentedtherapeuticpropertiesinthesettingofacuterespiratorydistresssyndrome
_version_	1718406346461675520

Mesenchymal Stem Cells Reconditioned in Their Own Serum Exhibit Augmented Therapeutic Properties in the Setting of Acute Respiratory Distress Syndrome

Ejemplares similares